LGM Pharma Expands CDMO Manufacturing Capacity with $15 Million Investment in Texas and Colorado, USA
Friday, March 20, 2026
LGM Pharma has announced the second phase of its CDMO expansion strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado.
This follows a previously announced $6 million investment in Rosenberg in 2025, bringing the company’s total investment across both sites to $15 million. The expansion aims to increase commercial manufacturing capacity, strengthen research and development capabilities, and meet growing demand for U.S.-based drug product manufacturing.
At the Rosenberg facility, $4 million will be invested to expand commercial-scale manufacturing suites for suppositories, driven by rising demand, particularly in women’s health products. The upgrades will also enhance R&D capabilities for formulation and scale-up of suppositories, solutions, suspensions, and semi-solid products. The site will remain operational during the upgrade process, which is already underway.
In Colorado Springs, the company will invest $5 million to expand commercial manufacturing capacity for specialised oral solid dose (OSD) products, including orally disintegrating tablets (ODTs). This facility serves as a key centre for OSD development and will support increasing demand for domestic manufacturing. The global OSD CDMO market was valued at $43.65 billion in 2024, with North America accounting for a significant share of manufacturing activity.
The investment reflects a broader strategy to strengthen pharmaceutical supply chains within the United States by combining domestic drug product manufacturing with global active pharmaceutical ingredient (API) sourcing. This integrated approach is intended to improve supply chain resilience, enhance visibility, and support the transition from development to commercialisation.
LGM Pharma also supports drug substance programmes, including 505(b)(2), NDA, and ANDA pathways, through a network of more than 220 pre-qualified API manufacturers worldwide. By integrating global API sourcing with expanded U.S.-based finished dose development and manufacturing, the company aims to provide end-to-end support across the product lifecycle.
The earlier phase of expansion in Rosenberg included improvements such as enhanced track-and-trace serialisation systems and increased production capacity, which have now been completed. The current phase is being carried out while maintaining full operations at both sites, with a focus on ensuring continuity of supply, maintaining quality standards, and scaling capacity in line with market demand.
Source: lgmpharma.com
